Integrating omics techniques and culture-independent systems may improve the detection of persistent candidemia: data from an observational study.
Blood culture
Candidemia
Host-response
Omics
Rapid diagnostic tests
T2 magnetic resonance
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
13
11
2023
accepted:
06
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Blood cultures have low sensitivity for candidemia. Sensitivity can be improved by the culture-independent system T2 Magnetic Resonance (T2). SeptiCyte RAPID is a host response assay quantifying the risk of infection-related inflammation through a scoring system (SeptiScore). We investigate the performance of SeptiScore in detecting persistent candidemia as defined by conventional cultures and T2. This is a prospective multicentre observational study on patients with candidemia. Blood cultures and blood samples for assessment by T2 and SeptiCyte were collected for 4 consecutive days after the index culture. The performance of SeptiScore was explored to predict persistent candidemia as defined by (1) positive follow-up blood culture (2) either positive follow-up blood culture or T2 sample. 10 patients were enrolled including 34 blood collections assessed with the 3 methods. Overall, 4/34 (12%) follow-up blood cultures and 6/34 (18%) T2 samples were positive. A mixed model showed significantly higher SeptiScores associated with persistent candidemia when this was defined as either a positive follow-up blood culture or T2 sample (0.82, 95%CI 0.06 to 1.58) but not when this was defined as a positive follow-up blood culture only (-0.57, 95%CI -1.28 to 0.14). ROC curve for detection of persistent candidemia by SeptiScore at day 1 follow-up showed an AUC of 0.85 (95%CI 0.52-1.00) when candidemia was defined by positive follow-up blood culture, and an AUC of 1.00 (95%CI 1.00-1.00) when candidemia was defined according to both methods. Integrating transcriptome profiling with culture-independent systems and conventional cultures may increase our ability to diagnose persistent candidemia.
Identifiants
pubmed: 39174996
doi: 10.1186/s12941-024-00736-w
pii: 10.1186/s12941-024-00736-w
doi:
Types de publication
Journal Article
Observational Study
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Informations de copyright
© 2024. The Author(s).
Références
Kang SJ, Kim SE, Kim UJ, Jang HC, Park KH, Shin JH, et al. Clinical characteristics and risk factors for mortality in adult patients with persistent candidemia. J Infect. 2017;75(3):246–53. https://doi.org/10.1016/j.jinf.2017.05.019 .
doi: 10.1016/j.jinf.2017.05.019
pubmed: 28587831
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice Guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. https://doi.org/10.1093/cid/civ933 .
doi: 10.1093/cid/civ933
pubmed: 26679628
Clancy CJ, Nguyen MH. Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92. https://doi.org/10.1093/cid/cit006 .
doi: 10.1093/cid/cit006
pubmed: 23315320
Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR 3, et al. Detecting infections rapidly and easily for Candidemia Trial, Part 2 (DIRECT2): a prospective, Multicenter Study of the T2Candida panel. Clin Infect Dis. 2018;66(11):1678–86. https://doi.org/10.1093/cid/cix1095 .
Mylonakis E, Zacharioudakis IM, Clancy CJ, Nguyen MH, Pappas PG. Efficacy of T2 magnetic resonance assay in monitoring candidemia after initiation of antifungal therapy: the serial therapeutic and antifungal monitoring protocol (STAMP) trial. J Clin Microbiol. 2018;56(4). https://doi.org/10.1128/JCM.01756-17 .
Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol. 2016;11(1):103–17. https://doi.org/10.2217/fmb.15.111 .
doi: 10.2217/fmb.15.111
pubmed: 26371384
Verboom DM, Koster-Brouwer ME, Varkila MRJ, Bonten MJM, Cremer OL. Profile of the SeptiCyte LAB gene expression assay to diagnose infection in critically ill patients. Expert Rev Mol Diagn. 2019;19(2):95–108. https://doi.org/10.1080/14737159.2019.1567333 .
doi: 10.1080/14737159.2019.1567333
pubmed: 30623693
U.S. Food and Drug Administration. 510(k) Substantial equivalence determination decision summary SeptiCyte RAPID 2021 [ https://www.accessdata.fda.gov/cdrh_docs/reviews/K203748.pdf
StataCorp. Stata Statistical Software: Release 17. College Station. TX: StataCorp LLC. DOI; 2021.
Beyda ND, Amadio J, Rodriguez JR, Malinowski K, Garey KW, Wanger A, et al. In Vitro evaluation of BacT/Alert FA blood culture bottles and T2Candida Assay for Detection of Candida in the Presence of antifungals. J Clin Microbiol. 2018;56(8). https://doi.org/10.1128/JCM.00471-18 .
Munoz P, Vena A, Machado M, Martinez-Jimenez MC, Gioia F, Gomez E, et al. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study. J Antimicrob Chemother. 2018;73(suppl4):iv13–9. https://doi.org/10.1093/jac/dky048 .
doi: 10.1093/jac/dky048
pubmed: 29608752
Mangioni D, Bandera A, Peri AM, Muscatello A, Gori A. Transcriptome profiling and fast microbiology in sepsis diagnosis: a potential synergy we cannot neglect. J Crit Care. 2019;52:267–8. https://doi.org/10.1016/j.jcrc.2019.03.005 .
doi: 10.1016/j.jcrc.2019.03.005
pubmed: 30917890